Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOX and Gemcitabine-RT in Pancreatic Cancer
NCT02243358Phase 2Completed
- Sponsor
- Henry Ford Health
- Start
- Feb 2014
- Primary completion
- Jun 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil, gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Henry Ford Health. Started Feb 2014; status: completed.
02
Drugs
oxaliplatinfluorouracilgemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02243358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243358.